Beta user program for Nanoparticle analyser

纳米颗粒分析仪 Beta 用户程序

• 批准号: 830259
• 金额: $ 80.12万
• 依托单位: OXFORD HIGHQ LTD
• 依托单位国家: 英国
• 项目类别: Innovation Loans
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=830259
• 关键词: Beta; user; program; Nanoparticle; analyser

The last three decades have seen the widespread adoption and industrialisation of nanoparticles serving applications in many technology sectors, including healthcare, energy production, manufacturing industry and agriculture. In the pharmaceutical sector, at the heart of this progress is the ability to fill otherwise inert particle materials with highly toxic anti-cancer drugs or genetic materials and/or functionalise the surface to both mask their presence from the human immune response and to better target the release of the "payload" at a particular organ, tumour or cellular component. These developments have led to a series of scientific breakthroughs in the field of advanced therapeutics by using nanocarriers to deliver drugs where it is needed in the body and reducing toxicity to healthy organ and tissues.However, manufacturing of such "advanced therapies" is challenging as it requires fine tools to scrutinise nanoparticles 1000 times smaller than the width of a human hair. Oxford HighQ has developed a new technique providing the ability to characterise the composition of nanoparticles through their optical properties, more specifically their refractive indices. One could use this parameter to measure on a particle-by-particle basis the amount of therapeutic molecules loaded within/on a nanoparticle carrier. The limited footprint, ease-of-use and potential for this technique to be built in-line within a manufacturing process makes it particularly attractive to the pharmaceutical industry.This project will see the launch of an ambitious 12-month alpha- and beta-users programme, as well as providing the opportunity to develop and test novel upgraded sample-handling capabilities to meet customer demand. Working with experts in the nanomedicines field, we will focus on demonstrating the application of our unique capabilities against a wide variety of analytes and sample matrices, allowing us to unlock the true potential of Oxford HighQ's technology.

在过去的三十年里，纳米颗粒在许多技术领域得到了广泛的采用和工业化，包括医疗保健、能源生产、制造业和农业。在制药领域，这一进展的核心是能够用高毒性抗癌药物或遗传物质填充惰性颗粒材料和/或功能化表面，以掩盖它们的存在，使其免受人体免疫反应的影响，并更好地将“有效载荷”释放到特定器官，肿瘤或细胞成分。这些发展在先进疗法领域带来了一系列科学突破，通过使用纳米载体将药物输送到体内需要的地方，并减少对健康器官和组织的毒性。然而，制造这种“先进疗法”是具有挑战性的，因为它需要精细的工具来仔细检查比人类头发宽度小1000倍的纳米颗粒。Oxford HighQ开发了一种新技术，能够通过纳米颗粒的光学特性（更具体地说是折射率）来分析纳米颗粒的组成。可以使用该参数来在逐颗粒的基础上测量负载在纳米颗粒载体内/上的治疗分子的量。该技术占地面积有限，易于使用，并具有在生产过程中在线构建的潜力，因此对制药行业特别有吸引力。该项目将启动一项为期12个月的雄心勃勃的alpha和beta用户计划，并提供开发和测试新型升级样品处理能力的机会，以满足客户需求。与纳米医学领域的专家合作，我们将专注于展示我们对各种分析物和样品基质的独特能力的应用，使我们能够释放Oxford HighQ技术的真正潜力。